ZYUS — Zyus Life Sciences Share Price
Last trade - 00:00- CA$56.51m
- CA$64.11m
- CA$0.35m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.8 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 125.03 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -210.7% | ||
| Return on Equity | -118.64% | ||
| Operating Margin | -9174.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0 | 0 | n/a | 0.3 | 0.35 | 0.48 | 0.56 | 213.99% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ZYUS Life Sciences Corporation is a Canada-based life sciences company. It develops and commercializes novel cannabinoid-based pharmaceutical drug candidates for pain management. Its lead research program is focused on developing a highly purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its pre-and non-clinical studies provide the foundation for clinical investigations of its drug candidates in humans. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management.
Directors
- Charlotte Hepburn CHM
- Michael Kindy CFO
- Charles Burns IND
- Michael Detlefsen IND (57)
- William Mills IND
- Greg Nuttall IND
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- November 25th, 1944
- Public Since
- October 18th, 2000
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 74,357,741
- Address
- 204 - 407 Downey Road, SASKATOON, S7N 4L8
- Web
- https://www.zyus.com/
- Phone
- +1 3062422357
- Auditors
- KPMG LLP
Upcoming Events for ZYUS
Similar to ZYUS
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
FAQ
As of Today at 24:17 UTC, shares in Zyus Life Sciences are trading at CA$0.76. This share price information is delayed by 15 minutes.
Shares in Zyus Life Sciences last closed at CA$0.76 and the price had moved by -24.75% over the past 365 days. In terms of relative price strength the Zyus Life Sciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -33.1% over the past year.
The overall consensus recommendation for Zyus Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreZyus Life Sciences does not currently pay a dividend.
Zyus Life Sciences does not currently pay a dividend.
Zyus Life Sciences does not currently pay a dividend.
To buy shares in Zyus Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.76, shares in Zyus Life Sciences had a market capitalisation of CA$56.51m.
Here are the trading details for Zyus Life Sciences:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: ZYUS
Based on an overall assessment of its quality, value and momentum Zyus Life Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Zyus Life Sciences is CA$1.50. That is 97.37% above the last closing price of CA$0.76.
Analysts covering Zyus Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.24 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zyus Life Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -11.11%.
As of the last closing price of CA$0.76, shares in Zyus Life Sciences were trading -16.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zyus Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Zyus Life Sciences' management team is headed by:
- Charlotte Hepburn - CHM
- Michael Kindy - CFO
- Charles Burns - IND
- Michael Detlefsen - IND
- William Mills - IND
- Greg Nuttall - IND